Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome by Lawler, James V et al.
Cynomolgus Macaque as an Animal Model
for Severe Acute Respiratory Syndrome
James V. Lawler
1¤a, Timothy P. Endy
2¤b, Lisa E. Hensley
2, Aura Garrison
2, Elizabeth A. Fritz
2, May Lesar
3,
Ralph S. Baric
4, David A. Kulesh
5, David A. Norwood
5, Leonard P. Wasieloski
5, Melanie P. Ulrich
5, Tom R. Slezak
6,
Elizabeth Vitalis
6, John W. Huggins
2, Peter B. Jahrling
7¤c, Jason Paragas
2*
1 Infectious Diseases Department, National Naval Medical Center (NNMC), Bethesda, Maryland, United States of America, 2 Virology Division, United States Army Medical
Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America, 3 Radiology Division, National Naval Medical Center (NNMC); Bethesda,
Maryland, United States of America, 4 Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 5
Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America, 6 Lawrence
Livermore National Laboratory, Livermore, California, United States of America, 7 Headquarters Division, United States Army Medical Research Institute of Infectious Diseases
(USAMRIID), Fort Detrick, Maryland, United States of America
Funding: The research described herein
was sponsored by a consortium
consisting of the Department of the
Army, the National Institute of Allergy
and Infectious Diseases, National
Institutes of Health grant AI059136,
Lawrence Livermore National Laboratory,
and the Centers for Disease Control and
Prevention as part of the interagency
response to the SARS epidemic.
Competing Interests: The authors have
declared that no competing interests
exist.
Academic Editor: Joseph S. M. Peiris, The
University of Hong Kong, China
Citation: Lawler JV, Endy TP, Hensley LE,
Garrison A, Fritz EA, et al. (2006)
Cynomolgus macaque as an animal
model for severe acute respiratory
syndrome. PLoS Med 3(5): e149.
Received: July 5, 2005
Accepted: January 10, 2006
Published: April 18, 2006
DOI:
10.1371/journal.pmed.0030149
This is an open-access article distributed
under the terms of the Creative
Commons Public Domain declaration
which stipulates that, once placed in the
public domain, this work may be freely
reproduced, distributed, transmitted,
modified, built upon, or otherwise used
by anyone for any lawful purpose.
Abbreviations: ALT, alanine
aminotransferase; AP, anterior-posterior;
CJ, conjunctival(ly); CT, crossing
threshold; IB, intrabronchial(ly); icSARS-
CoV, infectious clone SARS-CoV; IN,
intranasal(ly); IV, intravenous; NHP,
nonhuman primate; pfu, plaque-forming
units; PID, postinfection day(s); PRNT,
plaque reduction neutralization test; Q-
PCR, reverse transcription polymerase
chain reaction; SARS, severe acute
respiratory syndrome; SARS-CoV, SARS-
associated coronavirus; WBC, white
blood cell
* To whom correspondence should be
addressed. E-mail: jason.paragas@det.
amedd.army.mil
¤a Current address: Division of Medicine,
United States Army Medical Research
Institute of Infectious Diseases
(USAMRIID),FortDetrick,Maryland,United
States of America
¤b Current address: Communicable
DiseasesandImmunologyDivision,Walter
Reed Army Institute of Research, Silver
Spring,Maryland,UnitedStatesofAmerica
¤c Current address: National Institute of
Allergy and Infectious Diseases (NIAID),
Bethesda, Maryland, United States of
America
ABSTRACT
Background
The emergence of severe acute respiratory syndrome (SARS) in 2002 and 2003 affected
global health and caused major economic disruption. Adequate animal models are required to
study the underlying pathogenesis of SARS-associated coronavirus (SARS-CoV) infection and to
develop effective vaccines and therapeutics. We report the first findings of measurable clinical
disease in nonhuman primates (NHPs) infected with SARS-CoV.
Methods and Findings
In order to characterize clinically relevant parameters of SARS-CoV infection in NHPs, we
infected cynomolgus macaques with SARS-CoV in three groups: Group I was infected in the
nares and bronchus, group II in the nares and conjunctiva, and group III intravenously.
Nonhuman primates in groups I and II developed mild to moderate symptomatic illness. All
NHPs demonstrated evidence of viral replication and developed neutralizing antibodies. Chest
radiographs from several animals in groups I and II revealed unifocal or multifocal pneumonia
that peaked between days 8 and 10 postinfection. Clinical laboratory tests were not
significantly changed. Overall, inoculation by a mucosal route produced more prominent
disease than did intravenous inoculation. Half of the group I animals were infected with a
recombinant infectious clone SARS-CoV derived from the SARS-CoV Urbani strain. This
infectious clone produced disease indistinguishable from wild-type Urbani strain.
Conclusions
SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the
majority of adult human cases of SARS; however, our results suggest similarities to the milder
syndrome of SARS-CoV infection characteristically seen in young children.
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In late 2002, Chinese health ofﬁcials reported an unusual
number of atypical pneumonia cases in Guangdong Province,
and within 2 months, the World Health Organization (WHO)
was alerted of an outbreak widespread throughout the
province [1]. By March 2003, the illness designated severe
acute respiratory syndrome (SARS) had spread to Hong
Kong, Singapore, Vietnam, and Toronto, Canada [2]. The
global SARS outbreak ended that July, but during its
existence the disease caused 774 fatalities and had a
signiﬁcant economic impact on Southeast Asia [3–5]. A
special concern was its predilection for nosocomial spread,
as 21% of SARS cases occurred in healthcare workers . In
certain local outbreaks, hospital staff accounted for over 50%
of cases, and nosocomial spread to other patients or family
members accounted for a signiﬁcant proportion of SARS
cases [6].
Developing adequate animal models for SARS is a high
research priority. Coronaviruses tend to have a limited range
of host species, but several animal species have been found to
support SARS-associated coronavirus (SARS-CoV) replica-
tion [7]. BALB/c mice were shown to support high levels of
viral replication in the respiratory tract after intranasal
challenge, and this model has been used to test SARS vaccines
[8–10]. Infection of an additional rodent model (the strain
129SvEv mouse) showed infection of the respiratory epithe-
lium after intranasal SARS-CoV challenge [11]. Domestic cats
and ferrets support viral replication after intratracheal
challenge, and ferret models have been used to study active
and passive immunization against SARS [12–14]. Research has
focused on several animal species as potential natural
reservoirs for SARS-CoV. Himalayan palm civets (Paguma
larvata) and raccoon dogs (Nyctereutes procyonoides) were found
to be susceptible to infection with a virus closely related to
human SARS-CoV [15]. Experimental infection of civets
produced clinical illness and histopathological evidence of
pneumonia [16]. Chickens and pigs challenged with SARS-
CoV had viral RNA in blood during the ﬁrst week post-
infection, but neither species appeared to support signiﬁcant
viral replication or manifested clinical illness [17]. Recently,
Li et al. [18] reported that several species of wild bats in China
are carriers of a coronavirus closely related to SARS-CoV. No
studies have evaluated animal model infection or patho-
genesis of recombinant infectious clone SARS-CoV (icSARS-
CoV) derived from a molecular clone [19].
Nonhuman primate (NHP) models of SARS-CoV infection
have yielded absent to moderate observable disease that has
not replicated the severity of human SARS [20–25]. Fever was
notably absent in all studies, except for one African green
monkey on day 3 postinfection [20]. All studies detected
SARS-CoV replication in one or several monkey species and
documented seroconversion, thereby conﬁrming established
infection. Aside from observable clinical symptoms, these
studies relied on virus shedding and histopathology speci-
mens from necropsy as objective markers of disease. Most
studies euthanized animals during the course of infection to
document histopathological disease. Only two studies fol-
lowed animals for more than 14 d after infection [20,22]. No
study has examined radiographic evidence of pulmonary
disease, which is one of the most prominent features of SARS
in humans.
In adult humans, SARS presents as a severe febrile
pneumonia [1]. It has been characterized as a three-phase
illness: a ﬁrst phase consisting of a ﬂu-like illness, followed by
a phase of lower respiratory tract disease, with a third phase
of clinical deterioration in a process resembling adult
respiratory distress syndrome [26]. Disease progression can
be somewhat slow, with onset of severe respiratory disease
occurring anywhere from 1 to 2 wk after initial symptoms
[27]. Pulmonary radiographic abnormalities are almost
universally reported in SARS cases [28]. However, early
radiographs may be normal, and there is clear evidence of
infection without radiographic abnormality in a small
number of cases [29,30]. Multifocal disease is present in 30–
50% of initial radiographs, and the majority of persons
progress to multifocal disease that peaks between 8 and 14 d
after symptom onset [28,31–34]. Severe disease develops in up
to 30% of patients, with the most ill developing diffuse or
conﬂuent airspace consolidation consistent with adult respi-
ratory distress syndrome [28,31,33].
In contrast to adults, SARS in young children tends to be a
relatively mild disease [35]. Adolescents can experience
signiﬁcant respiratory disease similar to adults, but younger
children generally do not [36–39]. Constitutional symptoms
such as myalgias, chills, and headache that are common in
adults are usually absent in children [35,40]. Children have a
shorter course of illness, most being afebrile by 7 d, and
generally do not develop pulmonary disease signiﬁcant
enough to require assisted ventilation or even supplemental
oxygen [36–39,41]. As a result, the WHO diagnostic criteria
were not reliable in identifying SARS in pediatric patients
[38]. Some experts have recommended the term ‘‘mild acute
respiratory syndrome’’ for SARS-CoV infection in children
[35].
Radiographic ﬁndings in children with SARS are also less
signiﬁcant than in adults, in both presentation and pro-
gression [40]. Up to 50% of children have normal initial chest
radiographs [35]. In children with abnormal radiographs,
unilateral, focal airspace disease predominates [36,37,39].
Most children have worsening of radiographic disease as
illness progresses, with multifocal or bilateral lung involve-
ment developing in 20–50% of cases [39,42]. Radiographic
abnormalities in children generally resolve quickly, within 6–
14 d [37,42,43].
In this report, we document the results of observational
studies of SARS-CoV and icSARS-CoV infection in nonhu-
man primates. These studies focused on clinical and virologic
parameters associated with infection in cynomolgus maca-
ques in an attempt to examine the underlying mechanism of
disease and to study a potential animal model for SARS.
Methods
Virus and Cells
SARS-CoV Urbani strain was obtained from the Centers
for Disease Control and Prevention (Tom Ksiazek) in Atlanta,
Georgia and had been passaged four times in Vero E6 cells
(American Type Culture Collection, Manassas, Virginia,
United States) before inoculation. Final preparations of
SARS-CoV in PBS that were used in infection procedures
(below) had a titer of 3 3 10
6 plaque-forming units (pfu)/ml.
SARS-CoV-speciﬁc antibody titers were determined by
plaque reduction neutralization test (PRNT) on the day of
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SARS-CoV Infection of NHPsinfection and at 8 wk postchallenge. PRNTs were performed
on conﬂuent Vero cells in 6-well plates as described [9].
Recombinant virus (icSARS-CoV) was used at passage 1 past
the initial transfection, and the derivation of this molecular
clone has already been reported [19]. The icSARS-CoV
preparation titered at 1.25 3 10
6 pfu/ml.
Animals and Procedures
Eight (one female and seven male) adult cynomolgus
macaques (Macaca fascicularis) weighing between 4.6 and 8.8
kg were infected (see below) with SARS-CoV in two separate
iterations (n ¼ 2 and n ¼ 6) of the experiment. Animals were
observed daily for 20 d postinfection. In the six animals that
constituted the second iteration, additional blood was drawn
on day 26 postinfection.
Animals were anesthetized for physical examination, and
blood was drawn once preinfection (on day minus 3 or 2) and
then every other day beginning on the day of infection (day
0). Anesthesia was achieved by intramuscular injection of
Telazol at 3 mg/kg. Anesthetized animals received a physical
examination, chest radiographs, saphenous vein blood draw,
and swabs of oral, nasal, and rectal mucosa. Feces were
collected from animal cages on blood draw days. A metabolic
pan with a stop-valve drain was used to collect urine.
Experiments were conducted in biosafety level-3 laborato-
ries. For procedures in animal rooms, personnel wore Tyvek
suits with double gloves and a powered air-purifying
respirator. Personnel handling the virus or potentially
contaminated clinical specimens in the laboratory used a
Class II biological safety cabinet while wearing a powered air-
purifying respirator.
All research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals and
adhered to principles stated in the Guide for the Care and
Use of Laboratory Animals. This research was conducted in a
facility fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Infection
NHPs were infected by various routes. Intranasal (IN)
infection consisted of 0.5 ml of virus preparation inoculated
directly into each nostril by syringe. Conjunctivial (CJ)
infection consisted of 0.5 ml inoculated into the inferior
conjunctival fornix of each eye. Intravenous (IV) infection
was achieved by direct injection of 1.0 ml into the saphenous
vein. For intrabronchial (IB) infection, a pediatric broncho-
scope was passed into the right mainstem bronchus, and 4 ml
of virus preparation was instilled.
Animals were infected in three groups. Group I (n ¼ 4)
animals were inoculated in the nares and bronchus (IN/IB),
group II (n ¼ 2) in the nares and conjunctiva (IN/CJ), and
group III (n¼2) intravenously (IV). All infections were carried
out under anesthesia as described above. Two animals (292Q
and 91–379) in group II were infected with the icSARS-CoV,
and the rest of the animals were infected with wild-type virus.
Radiographs
Upright anterior-posterior (AP) and lateral chest radio-
graphs were performed while animals were under anesthesia.
Digital radiographs were taken with a MinXray HF 100/300
(MinXray, Northbrook, Illinois, United States) portable X-ray
machine. Radiographs were digitally processed with a Fuji
FCR XG-1 Smart CR reader using Fuji Synapse software
(FUJIFILM Medical Systems USA, Stamford, Connecticut,
United States). Radiographs were read by a board-certiﬁed
chest radiologist (ML) who was blinded to route of infection
and clinical course of animals.
Hematology and Clinical Chemistries
Total WBC count, lymphocyte count (absolute and per-
cent), hemoglobin, hematocrit, platelet count, and red cell
indices were measured with a COULTER Ac T hematology
analyzer (Beckman Coulter, Fullerton, California). Albumin,
alkaline phosphatase, ALT, AST, amylase, BUN, creatinine,
total bilirubin, total protein, calcium, cholesterol, and glucose
were measured with a Vetscan blood chemistry analyzer
(Abaxis, Union City, California, United States).
Virus Genome Detection
Two real-time reverse transcription polymerase chain
reaction (Q-PCR) assays were developed to detect viral RNA
in NHP biosamples (Tables S1 and S2). These assays targeted
SARS-CoV genes POL and SMP respectively. Details of
development and testing of the SARS-CoV-speciﬁc Q-PCR
assays (Table S1) can be found in Protocol S1. RNA was
extracted from NHP biosamples using Trizol (Invitrogen,
Carlsbad, California, United States) according to the manu-
facturer’s recommendations. Puriﬁed RNA was analyzed on
the Ruggedized Advanced Pathogen Identiﬁcation Device
(RAPID, Idaho Technology, Salt Lake City, Utah, United
Table 1. Summary of Routes of Infection and Clinical Findings
Group Route Animal Sex Virus Overt Clinical Illness Radiographic Disease
I IB and IN 91–506 M WT Y N/D
a
41–309 M WT Y N/D
a
292Q F IC Y Y
91–379 M IC Y Y
II CJ and IN 91–477 M WT Y N
91–512 M WT Y Y
III IV 91–335 M WT N N
91–387 M WT N N
IC, recombinant icSARS-CoV Urbani; N/D, no data; WT, wild-type SARS-CoV Urbani.
aTechnical complications resulted in inadequate radiographic images that could not be interpreted for evidence of disease.
DOI: 10.1371/journal.pmed.0030149.t001
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SARS-CoV Infection of NHPsStates) as follows: 5 ll of RNA from each sample was added to
the appropriate SARS-speciﬁc assay master mix (15 ll) and
cycled in the LightCycler as described in Protocol S1. All test
runs included at least one positive control that contained
0.075 pfu equivalents of plaque-puriﬁed SARS-CoV RNA and
two no-template controls: reagent and sample. Quantiﬁed Q-
PCR results were reported for the POL TaqMan assay.
Virus Isolation
Virus isolation was attempted from selected biosamples
from the second iteration of six animals. Specimens with a Q-
PCR crossing threshold (CT) of less than 32 CT underwent
culture for viral isolation. Brieﬂy, 200 ll of media from swab
samples was used to inoculate T25 ﬂasks of Vero E6 cells
(ATCC). Flasks were monitored daily for cytopathic effect.
Viral culture supernatants were prepared and titered using
viral plaque assay. Cells were scraped, pelleted, and ﬁxed in
2% glutaraldehyde in 0.1 M Millonig’s phosphate buffer. Cell
pellets were washed, postﬁxed in 1% osmium tetroxide,
dehydrated and embedded in Poly/Bed 812 resin (Polyscien-
ces, Warrington, Pennsylvania, United States). Ultrathin
sections were stained with uranyl acetate and lead citrate
and examined by transmission electron microscopy for
virions.
Results
Clinical Observations
We infected eight cynomolgus macaques with SARS-CoV in
three groups: Group I (n ¼ 4) was infected in the nares and
bronchus, group II (n ¼ 2) in the nares and conjunctiva and
group III (n ¼ 2) intravenously. Basic clinical ﬁndings are
summarized in Table 1. All animals in groups I and II
Figure 1. Chest Radiographs
Anterior-posterior (AP) (A) and lateral (B) chest radiographs from 8 d postinfection for animal 91–379 show focal airspace disease in the right lower lobe
that obscures the right costophrenic angle. Air bronchograms can be seen on the lateral view. Radiographs showing AP (C) and lateral (D) views from
day 8 for animal 91–512 demonstrate subtle bilateral perihilar airspace disease visible on the AP film. Radiographs of animal 292Q on day 6 (E, F) reveal
airspace disease involving the right lower lobe, left lingula, and perihilar right upper lobe. Lower lobe disease is clearly seen on the lateral view (F).
DOI: 10.1371/journal.pmed.0030149.g001
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SARS-CoV Infection of NHPsdisplayed mild to moderate symptoms of illness beginning
between postinfection days (PID) 2–4. Observed symptoms
included decreased activity, decreased feeding, snufﬂing, and
mildly labored breathing. Animal activity and appearance
returned to baseline by PID 12–14 in all cases. Animals
infected with wild-type SARS-CoV or with icSARS-CoV both
displayed clinical signs of illness. We observed no overt
clinical illness in the group III animals, which were infected
intravenously.
None of the animals developed a measurable fever.
Continuous telemetry monitoring in four animals revealed
no signiﬁcant changes in temperature, heart rate, blood
pressure, or left ventricular pressures (unpublished data).
Radiographs
Chest radiograph results were available for six of the
animals. Three of them exhibited radiographic evidence of
pulmonary disease. The two animals infected by the IV route
(group III) had no signiﬁcant change in chest radiographs,
while three of four animals infected by a mucosal route
(groups I and II) developed radiographic disease (Figure 1).
Two animals with radiographic disease were infected with the
icSARS-CoV (both group I) and one animal (group II) was
infected with wild-type virus.
Of the three animals with radiographic evidence of disease,
two (292Q and 91–379) were infected by the IB/IN route
(group I) and one (91–512) was infected by the CJ/IN route
(group II). All developed signiﬁcant airspace disease on PID 6.
The group II animal had normal radiographs until PID 6,
when it developed a perihilar left upper lobe inﬁltrate. By
PID 8, there was perihilar disease in the right upper lobe as
well. These ﬁndings were relatively subtle and began to
resolve on PID 12. They were still evident, albeit continuing
to resolve, by PID 18. The two group I animals had subtle
changes on PID 2 (right mid-lower lobe for 292Q, right lower
lobe for 91–379). Radiographic appearance was unchanged
on PID 4 in 292Q, but 91–379 did have a slight increase in the
right lower lobe opacity. On PID 6, both animals had
dramatic radiographic changes, with 292Q developing in-
creasing lower lobe disease and new right-upper lobe airspace
disease and 91–379 showing a signiﬁcant increase in the right
lower lobe consolidation. Both 292Q and 91–379 had
increasing disease on PID 8 and demonstrated slight
improvement by PID 10. Changes completely resolved by
PID 14 in 91–379, but mild residual and resolving changes
were still evident in 292Q on PID 18.
Hematology
Blood cell counts reﬂected only minimal changes. Infected
animals did demonstrate a statistically signiﬁcant trend of
rising total leukocyte (WBC) count during the course of
infection (Figure S1A–S1C). Mean WBC count rose from 5.53
10
9 per liter on day 0 to a peak of 10.6310
9 per liter on PID
12 (p ¼ 0.006, two-tailed paired t-test), but no animal had a
WBC count above the USAMRIID upper limit of normal of
15.0 3 10
9 per liter. This trend in WBC count was observed
across all groups, regardless of route of exposure. Absolute
and percent lymphocytes did not follow a consistent trend
(Figure S1D–S1I). Several aberrant platelet counts were
noted, thought to be secondary to clotting or platelet
clumping. Overall, no signiﬁcant change in platelet count
was observed for any group. No abnormal trends were noted
in other hematologic parameters (Figure S1J–S1O).
Serum Chemistries
Alkaline phosphatase (Figure S2A–S2C) became elevated in
two group I animals, peaking at 450 units per liter
(USAMRIID upper limit of normal ¼ 288 U/l) on day 12 for
one (41–309) and at 340 units per liter on day 18 for the other
(292Q). Alkaline phosphatase was elevated at two consecutive
data points for both animals and had returned to normal by
day 26. Other liver-associated parameters did not reﬂect any
hepatic injury or dysfunction in these animals (Figure S2D–
S2I). One animal (91–506) in group I had an isolated elevated
alanine aminotransferase (ALT) of 229 units per liter
(USAMRIID upper limit of normal ¼ 85 U/l) on day 2 (Figure
S2D). The ALT was within normal range on every other day
for this animal, and other liver-associated parameters
remained within normal limits during the course of infection.
Serum blood urea nitrogen (BUN) and creatinine did not
suggest a signiﬁcant change in renal function in any animal
during the course of SARS-CoV infection (Figure S2J–S2O).
Neutralizing Antibodies
All animals had convalescent anti-SARS-CoV antibodies
detected by plaque reduction neutralization test (PRNT
performed 8 wk postinfection. Neutralizing antibodies were
undetectable at baseline in all animals. PRNT50 results are
shown in Table 2. Group I animals had higher titers of
neutralizing antibody, but comparison of geometric mean
titers between groups by analysis of variance showed no
statistical difference.
Viral Detection in Biosamples
Viral RNA was detected by real-time Q-PCR in biosamples
taken from all animals (Table 3). In particular, viral genome
in nasal swabs and urine was detected in all animals regardless
of route of exposure. Viremia was not a common ﬁnding. The
two group III (infected IV) animals had virus detected in
blood shortly after inoculation, as would be expected, but
only one of these animals (91–335) had detectable viremia
after day 0. From either group I or II only one animal (91–
512) had detectable viremia, with positive Q-PCRs on PID 8
and 20.
Virussheddingintheurinewasuniversal,detectedasearlyas
PID 2 and as late as PID 23. Urinary excretion of virus was a
predominantly late phenomenon. Shedding from the naso-
Table 2. PRNT50 Antibody Titers at Baseline (Day 0) and During
Convalescence (8 wk Postinfection)
Animal Group Virus Baseline Convalescent
91–506 I WT ,1:20 1:320
41–309 WT ,1:20 1:320
292Q IC ,1:20 1:320
91–379 IC ,1:20 1:80
91–477 II WT ,1:20 1:80
91–512 WT ,1:20 1:80
91–335 III WT ,1:20 1:80
91–387 WT ,1:20 1:80
IC, recombinant icSARS-CoV; WT, wild-type SARS-CoV Urbani.
DOI: 10.1371/journal.pmed.0030149.t002
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SARS-CoV Infection of NHPspharynx was detected in all animals, although it was more
common in animals challenged by mucosal route versus
intravenous route (average number of days, 6.8 versus 2, p ¼
0.041,ANOVA).Oneanimal (91–477) had apositive nasal swab
on day 0. This result was probably due to cross-contamination
atthetimeofcollection.Threeanimals(292Q,91–477,and91–
512)thathadthemostprolongedandpersistentnasalshedding
had been inoculated by mucosal routes.
Detection of viral RNA in rectal or fecal specimens varied
with the route of infection (Table 3). Group II animals had
viral genome detected in at least ﬁve contiguous rectal swabs
or fecal specimens (spanning 10 d) and had positive speci-
mens on an average of 7.5 d. Viral RNA was found in two out
of four of the group I animals (1 d each) and was undetected
in group III animals (p ¼ 0.001, ANOVA).
A total of 30 biosamples with a Q-PCR crossing threshold
under 32 from ﬁve animals were cultured. Live virus was
isolated from 20 of these samples (Table 3). Two samples with
crossing threshold over 32 and one negative control specimen
had negative culture results. Both wild-type and infectious
clone SARS-CoV were isolated from culture. Transmission
electron micrography of positive cell cultures revealed
spherical virions on the surface of cells as well as maturing
virions budding into smooth-walled vesicles consistent with a
coronavirus (Figure S3).
Discussion
This study demonstrated that cynomolgus macaques
infected with SARS-CoV develop clinical disease with
pulmonary radiographic ﬁndings. The presence of radio-
graphic disease appeared to depend upon the route of
infection. Of four animals challenged by a mucosal route
(groups I and II), three had radiographic evidence of
pulmonary disease. Radiographic disease developed by PID
6, and it peaked and resolved rapidly. Neither animal in the
intravenous challenge group (group III) developed radio-
graphic disease.
SARS-CoV replication was detected at a variety of sites in
infected animals. The virus displayed tropism for the upper
respiratory mucosa, but replication at distal sites reﬂects
systemic viral infection. Data from human studies suggest that
nasopharyngeal shedding of SARS-CoV increases for the ﬁrst
10 d of symptoms [26]. We detected no consistent pattern in
nasopharyngeal shedding. Viremia was not a prominent
feature and was found in only one of the intravenously
infected animals at days 2 and 6.
In our study, frequency and source of SARS-CoV genome
detection correlated with route of inoculation. Animals
infected intravenously (group III) had a paucity of positive
specimens. Viruria appearing after day 10 was the only
persistent ﬁnding in these animals (Table 3). Animals infected
mucosally (groups I and II) had a greater number of positive
specimens from nasal swabs and throat swabs. The two group
II animals had the most positive specimens and were the only
animals to have signiﬁcant fecal or rectal shedding. Presence
and degree of viral shedding did not appear to correlate with
radiographic disease. The group II animal (91–477) that did
not develop radiographic disease had extensive viral shedding
from the nasopharynx, urine, and gastrointestinal tract.
No unusual changes in hematologic and serum chemistry
parameters were observed (Figures S1 and S2). WBC count
increased signiﬁcantly but remained within our laboratory’s
normal range. Unlike experience in humans and other studies
with NHPs, we did not detect a measurable change in
lymphocyte or platelet counts [22,23,25,44–47]. Renal and
hepatic markers did not suggest signiﬁcant derangement
during the course of infection, although alkaline phosphatase
was elevated brieﬂy in two animals (Figure S2A). We cannot
explain the origin of this transient elevation in alkaline
phosphatase, but the absence of abnormalities in other liver-
associated enzymes and the brief duration of the abnormal
values make signiﬁcant hepatic or bone injury unlikely.
Disease produced by wild-type SARS-CoV Urbani and by
icSARS-CoV was clinically indistinguishable. Observable
symptoms and laboratory parameters did not vary between
the two viruses. Both icSARS-CoV-challenged animals devel-
oped radiographic disease. Of the two animals infected with
wild-type virus by a mucosal route, only one developed
radiographic disease, and radiographic ﬁndings were rela-
tively subtle. We cannot exclude the possibility that icSARS-
CoV produces more signiﬁcant pulmonary disease, but the
difference in ﬁndings is more likely related to route of
infection and dose. Animals that received icSARS-CoV (both
in group I) were infected in the bronchus with a higher dose
of virus. Importantly, the fact that recombinant icSARS-CoV
produced disease clinically similar to its Urbani parent
supports the hypothesis that the molecular clone recapit-
ulates the disease phenotype in the macaque. These ﬁndings
suggest that SARS-CoV is the sole cause of SARS, without the
involvement of coinfecting or passenger agents. Models using
icSARS-CoV may pave the way for identiﬁcation of genetic
determinants of pathogenesis.
All animals seroconverted in convalescence, with neutral-
izing antibodies detected 8 wk after infection (Table 2).
Groups I and II had higher neutralizing antibody titers than
group III. This difference was not statistically signiﬁcant,
perhaps due to the low number of animals involved. Infection
did appear to impart protective immunity, at least in the
short term. Six animals were rechallenged by IN and CJ
inoculation of SARS-CoV 13 wk after initial infection. All six
displayed no clinical signs of disease and had normal chest
radiographs (unpublished data). These six animals included
the two animals initially challenged with the recombinant
icSARS-CoV, demonstrating that molecularly cloned virus
induced protective immune responses against its wild-type
parent.
Our study has some potential limitations. This was an
observational study that was not designed to achieve
statistical signiﬁcance in all parameters measured. We
infected a small number of animals by each route, so we
may not have observed the entire spectrum of disease severity
[29,30,48]. In order to ensure virus delivery to lower
respiratory mucosa, we instilled a larger volume of virus
preparation through the bronchoscope to group I animals.
Q-PCR results from nasal swabs (N), pharyngeal swabs (T), blood (B), rectal swabs (R), feces (F) and urine (U) expressed as genome copy number. (–) indicates not detected.
aInfected with icSARS CoV infections clone.
bLive virus isolated from sample.
DOI: 10.1371/journal.pmed.0030149.t003
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SARS-CoV Infection of NHPsThus group I received a total inoculum 2.5 times that of
group II and ﬁve times that of group III. Finally, we used a
relatively high inoculum of virus. Although the infectious
dose (ID50) in humans is unknown, it is likely that the dose we
administered is signiﬁcantly larger. We used this high
inoculum with the intention of producing a more uniform
presentation of disease in the study animals.
Our experience offers contrast to previously published
studies of SARS-CoV infection in nonhuman primates [20–
23,25]. We found mild to moderate symptomatic disease in
cynomolgus macaques infected mucosally. Fouchier et al. [21]
and Kuiken et al. [23] described more signiﬁcant clinical
disease in cynomolgus macaques, with lethargy, rash, and
respiratory distress evident in some animals. Bukreyev et al.
[22] and McAuliffe et al. [20] recount no overt disease in
rhesus, cynomolgus, or African green monkeys challenged
with SARS-CoV Urbani, but they report a higher degree of
viral replication in African greens. One African green
monkey was also noted to have a single febrile temperature
on PID day 3 [20]. Rowe et al. [25] examined SARS-CoV
infection in cynomolgus and rhesus macaques and reported
only minimal symptomatic disease. In the Rowe et al. study, as
in ours, symptomatic infection was detected only in animals
challenged mucosally and not in animals infected IV [25].
Evidence of persistent viral replication in the upper
airways has varied between studies. Rowe et al. [25] reported
a sparse number of positive nasal and oral swabs, although
one of each was positive at PID 12. In contrast, combined data
from Kuiken et al. [23] and Fouchier et al. [21] show nasal or
pharyngeal shedding in ﬁve of six animals. McAuliffe et al.
[20] detected respiratory tract shedding for 2–10 d after
infection. We found that mucosally infected animals had
universal shedding from the nasopharynx between PID 2 and
8 and had frequent shedding out to PID 23. We found
signiﬁcant and persisting virus presence in the urine and
feces as well. Other studies have not reported testing urine
for virus presence, although Kuiken et al. [23] report virus
detection by PCR at necropsy in the kidney or urinary
bladder of one animal each. McAuliffe et al. [20] found
positive fecal samples by RT-PCR only in African green
monkeys. Kuiken et al. [23] and Rowe et al. [25] tested rectal
swabs for presence of virus but found none positive.
Observed differences in model performance are difﬁcult to
explain but may be attributable to viral strain, dose or route
of infection. Bukreyev et al. [22] and McAuliffe et al. [20] also
used the Urbani strain of SARS CoV given by a similar route
(intranasal and intratracheal), but our clinical observations
were signiﬁcantly different. We used a different assay method,
but our total dose per animal was probably higher, as they
used 10
6 to 10
6.3 cell culture infective doses (also referred to
as TCID50). Fouchier et al. [21] and Kuiken et al. [23] used a
different strain of virus isolated from patient 5688. They
observed the most prominent clinical symptoms despite using
a similar dose (1 3 10
6 cell culture infective doses)
administered in the nares and trachea. Rowe et al. [25] used
a dose similar to ours (10
7 pfu) of SARS-CoV isolated from a
Canadian patient. Their route of delivery was also through
the nares and trachea.
The radiographs in our study present a much clearer
picture of pulmonary disease than have previous studies
using NHPs. In Kuiken et al. [23] and Fouchier et al. [21],
pneumonia was evident in pathological specimens from
necropsy at PID 6, but animals were not followed past this
point. Only two of eight animals in the study by Rowe et al.
[25] had pathological evidence of lung disease, but necropsies
were performed 14 d postinfection. McAuliffe et al. [20]
found histopathologic evidence of viral lung infection on PID
2 that was resolving by PID 4. None of these studies used any
other objective method to measure pulmonary disease.
The radiographic appearance of pneumonia in our study
may afford insight into NHP models of SARS. Radiography
provides an objective but dynamic measure of pulmonary
disease. Our radiographic ﬁndings are similar to radiographs
of humans with less-severe cases of SARS [28,31,32]. There is
growing evidence that SARS may present as mild or indolent
disease in adults [29,30,48]. Such mild disease in adults does
appear to be an exception, however. Overall, our experience
conﬁrms that clinical disease from SARS-CoV infection in
NHPs does not closely reproduce SARS in adult humans.
The similarity between our ﬁndings and SARS in children
deserves further examination. We observed unifocal or
multifocal radiographic disease resolving quickly instead of
progressing to severe diffuse disease, which is consistent with
ﬁndings in children with SARS [37,39,42,43]. Absence of fever
may not be as signiﬁcant as it would seem. In published
reports, children with SARS did present with fever, but the
data are biased, because fever was universally included in case
deﬁnitions [36–39,41]. Fever in children less than ten years
old who are diagnosed with SARS tends to be relatively mild
and short in duration [36–39,41]. In these reports, it is
possible that children with mild clinical illness from SARS
who did not develop a signiﬁcant fever may have remained
undiagnosed. This premise is supported by at least one
documented case of SARS in an adult without fever [49].
Hematologic ﬁndings, particularly lymphopenia, are more
prevalent in children with SARS [36–39,41] than in the
macaques of our study, but Rowe et al. [25] did ﬁnd
lymphopenia and thrombocytopenia in their animals.
Understanding the differences between SARS in adults and
in children may be very important in unraveling the under-
lying pathogenesis of SARS. Adults and children appear to
have similar levels of SARS-CoV viremia associated with
infection, implying that levels of viral replication are similar
in both groups [50]. Adults with SARS have signiﬁcantly
increased serum levels of inﬂammatory cytokines and chemo-
kines [51–53]. Activation of inﬂammatory cytokines in
children with SARS may be less dramatic [54], and prelimi-
nary data suggest that this is the case in NHPs as well [25].
Thus, immune response may account for variations in SARS
severity between age groups and even species.
We have described our experiments with SARS-CoV
infection by a variety of routes in cynomolgus macaques.
Wild-type SARS-CoV and recombinant icSARS-CoV pro-
duced similar disease in our macaque model. As in prior
studies, we found overt clinical disease in animals infected by
mucosal routes that was much less severe than adult human
SARS. We found radiographic pulmonary disease in most of
these animals that resembled radiographic ﬁndings in human
SARS. Overall, the disease we observed had some similarities
to SARS in young children. Further study is needed to
determine the applicability of NHP models to the study of
SARS.
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Figure S1. Line Graphs of Complete Blood Count Results
Hematology results from cynomolgus macaques infected with SARS-
CoV on day 0. Included are results for WBC count (A–C); absolute
lymphocyte count (D–F); percent lymphocytes (G–I); hematocrit (J–L);
and platelet count (M–O). Results are grouped by route of infection:
group I, intrabronchial þ intranasal (A, D, G, J, M); group II,
conjunctivalþintranasal (B, E, H, K, N); group III, intravenous (C, F, I,
L, O).
Found at DOI: 10.1371/journal.pmed.0030149.sg001 (4.7 MB DOC).
Figure S2. Line Graphs of Serum Chemistry Results
Serum chemistry results from cynomolgus macaques infected with
SARS-CoV on day 0. Included are results for alkaline phosphatase (alk
phos) (A–C); alanine aminotransferase (ALT) (D–F); albumin (G–I);
blood urea nitrogen (BUN) (J–L), and creatinine (M–O). Results are
grouped by route of infection: group I, intrabronchialþintranasal (A,
D, G, J, M); group II, conjunctival þ intranasal (B, E, H, K, N); group
III, intravenous (C, F, I, L, O).
Found at DOI: 10.1371/journal.pmed.0030149.sg002 (5.4 MB DOC).
Figure S3. Electron Micrograph of SARS-CoV from Cell Culture
Transmission electron micrograph of Vero cell infected with SARS-
CoV isolate recovered from sample from infected nonhuman
primates shows sphere-shaped virions on the surface of the cell as
well as maturing virions budding into smooth-walled vesicles.
Found at DOI: 10.1371/journal.pmed.0030149.sg003 (3.3 MB PSD).
Protocol S1. Development of SARS-CoV-Speciﬁc Q-PCR Assays
Found at DOI: 10.1371/journal.pmed.0030149.sd001 (38 KB DOC).
Table S1. Primer and Probe Sequences for SARS-CoV-Speciﬁc Q-
PCR
Primer and probe names, sequences, and ﬁnal concentrations for two
SARS-CoV speciﬁc Q-PCR assays developed to detect SARS-CoV
genome in infected NHPs.
Found at DOI: 10.1371/journal.pmed.0030149.st001 (31 KB DOC).
Table S2. Testing of SARS Real-Time PCR Assays
Results of POL-minor binding groove (MGB) and SMP-MGB assays for
samples spiked with SARS coronavirus versus samples spiked with
non-SARS coronaviruses.
Found at DOI: 10.1371/journal.pmed.0030149.st002 (34 KB DOC).
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Patient Summary
Background. The emergence of severe acute respiratory syndrome
(SARS) in Asia 2003 in many ways served as reminder of how a new
infectious disease had the potential to cause huge economic disruption,
as well as being of substantial public health importance. Although the
cause of the disease was discovered quite quickly—a new virus known as
SARS-associated coronavirus (SARS-CoV) (corona being a description of
the virus’s spiky, crown-like appearance when seen under an electron
microscope)—experts differed in their opinion on how the disease
should be treated, and no vaccine has yet been developed for it.
Why Was This Study Done? Previously identified human coronaviruses
caused only mild respiratory infections. Hence researchers wanted to
understand exactly how this new virus caused disease. Infecting animals
with the virus was a crucial part of this research. Researchers had already
given the virus to a number of animal species, ranging from mice to pigs
to monkeys, but none had shown symptoms that were similar to those
seen in humans.
What Did the Researchers Do and Find? They infected a small number
of macaques with the SARS-CoV, either into the nose and throat, nose
and eye, or intravenously. Some of the animals were given the virus
isolated from humans infected with disease, and others were given a
genetically engineered virus that was identical in sequence to this virus.
The virus was able to multiply in all the macaques, and all developed
antibodies to the virus—evidence of an immune response. Chest
radiographs from several animals infected via the nose, throat, or eye
showed pneumonia that was at its worse between days 8 and 10 after
infection. Overall, giving the virus intravenously rather than by these
other routes produced a less severe infection. Also, there were no
differences in signs or symptoms in animals given the natural virus rather
than the engineered one.
What Do These Findings Mean? Although necessarily the number of
animals infected was very small, the researchers were able to get some
interesting results. The infected animals did not get severe disease, but
rather the disease was more like that seen in infected children.
Nonetheless, this animal model of disease may well be useful in
developing therapies and vaccines against this illness. In addition, they
showed that the engineered virus produce the same symptoms as the
one isolated from humans, which suggests that no other viruses are
involved in causing SARS
Where Can I Get More Information Online? MedlinePlus has a page of
links to SARS information:
http://www.nlm.nih.gov/medlineplus/severeacuterespiratorysyndrome.
html
The CDC also has a fact sheet on SARS:
http://www.cdc.gov/ncidod/sars/factsheet.htm
The WHO has a Web site with up-to-date information on SARS:
http://www.who.int/csr/sars
PLoS Medicine | www.plosmedicine.org May 2006 | Volume 3 | Issue 5 | e149 0686
SARS-CoV Infection of NHPs